WeVote
Log In

Bill

Bill

HB 6573

AN ACT REQUIRING NEWBORN SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY.

2025 Regular Session Introduced by John-Michael Parker

Connecticut bill mandates newborn screening for Duchenne Muscular Dystrophy to enable early intervention and slow disease progression in affected infants.

REF. TO JOINT COMM. ON Public Health
#children #medicaltests
0
WeVote Research Nonpartisan
Bill Summary · HB 6573

Legislative bill overview

HB 6573 would mandate that Connecticut include Duchenne Muscular Dystrophy (DMD) screening in its newborn screening program. Currently, most states do not routinely screen for DMD at birth, though the condition can be detected through measurement of creatine kinase (CK) levels in dried blood spots already collected for other screenings.

Why is this important

Early detection of DMD enables families to begin immediate interventions—including physical therapy, cardiac monitoring, and corticosteroid treatment—that can significantly slow disease progression and improve outcomes. DMD is a severe, progressive genetic disorder affecting approximately 1 in 3,500 male births, causing progressive muscle weakness and typically leading to wheelchair dependence by adolescence and reduced lifespan.

Potential points of contention

  • Cost and implementation: Adding DMD to newborn screening programs requires laboratory infrastructure, staff training, and ongoing funding; costs may be passed to healthcare systems or taxpayers
  • False positives and anxiety: CK-based screening can produce elevated results from benign conditions (carriers, other myopathies), potentially causing parental distress before confirmatory testing
  • Limited treatment landscape: While early detection enables interventions, no cure exists for DMD; some stakeholders question screening value when curative therapies remain unavailable, though newer treatments show promise

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.